trending Market Intelligence /marketintelligence/en/news-insights/trending/Ed6wA1tYhrzIlQKjKCelEA2 content esgSubNav
In This List

US FDA approves Medicure, Carmel's cardiovascular drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US FDA approves Medicure, Carmel's cardiovascular drug

Medicure Inc. said the U.S. Food and Drug Administration approved Carmel Biosciences Inc.'s Prexxartan oral solution in the U.S.

The cardiovascular drug is the first and only approved oral liquid dosage form of the angiotensin II receptor blocker valsartan in the U.S.

In October, Medicure acquired a license to sell and market Prexxartan in the U.S. and its territories from Carmel Biosciences for a seven-year term, with potential extensions to the term available.

Medicure intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date during the first half of 2018.